Parkinson's disease therapeutics companies specialize in the development of medications and treatments for Parkinson's disease, a neurodegenerative disorder affecting movement and motor function. These companies work towards the discovery of novel therapies, including dopamine agonists and levodopa formulations, to manage symptoms and improve the quality of life for individuals living with Parkinson's disease.
AbbVie Launched their Duopa Intralipid (levodopa/carbidopa intestinal gel) for patients with advanced Parkinson's disease experiencing "off" periods when medication effectiveness diminishes. Collaborating with research institutions on exploring alpha-synuclein targeting therapies, a potential approach to slow disease progression.
Roche Received FDA approval for YELMIO (foneprezil) for the treatment of levodopa-induced dyskinesia, a common side effect of Parkinson's disease medication. Focusing on developing gene therapy candidates for Parkinson's disease, aiming to address the underlying cause of the disease.
Biogen Conducted a positive Phase 2 trial of BIIB0501, a potential neuroprotective therapy for Parkinson's disease, showing promise in slowing disease progression. Partnering with patient advocacy groups to raise awareness about Parkinson's disease and support research efforts.
Novartis Received FDA approval for Kynmobi (apomorphine hydrochloride injection) for continuous subcutaneous infusion to treat "off" periods in Parkinson's disease. Investing in research on stem cell therapies for Parkinson's disease, exploring potential for regenerating dopamine-producing neurons.
Denali Therapeutics Presented encouraging data at the Alzheimer's Association International Conference on their investigational Tau aggregation inhibitor for Parkinson's disease. Focused on developing therapies targeting different aspects of the disease beyond just dopamine replacement.
Parkinsons Disease Therapeutics Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)